A Univariate Analysis of Factors Influencing Survival in Advanced Pancreatic Neuroendocrine Tumors Abstract #1403

Introduction: Pancreatic neuroendocrine tumors (pNET) are rare and display clinical heterogeneity.
Aim(s): We propose a clinical risk stratification tool for well differentiated, metastatic pNET.
Materials and methods: Retrospective study using clinical, pathological and laboratory variables for univariate analyses in a consecutive multicenter cohort (N=312) with pathologically confirmed, sporadic, well differentiated (grade 1 or 2), metastatic (Stage IV) pNET diagnosed between 1993 and 2010 with a minimum follow-up of 5 years. Data are presented as the mean with standard deviation (SD) and/or 95% confidence interval (CI). Overall survival was calculated using the Kaplan-Meier method with log-rank testing for potentially prognostic factors.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Henning Jann
Keywords: pNET, prognosis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1361 Evaluation of the Therapeutic Approaches Impacting on the Survival of Patients with an Advanced Pancreatic Neuroendocrine Tumor
Introduction: The therapeutic approaches in metastatic pancreatic neuroendocrine tumors (pNET) are currently used as a palliative strategy to control symptoms and potentially improving patient survival.
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD Sebastian Krug
Keywords: pNET
#663 Comparing Chinese Pancreatic Neuroendocrine Tumors with Americans: Their Clinicopathological Features and Prognosis
Introduction: It is unknown if clin-patho features of PNET pts are different between China and USA, the largest country in the east and west, respectively.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Dr. X.W. Qiao
Authors: Qiao X W, Tang L, Zhu L M, Chen J, ...
#1932 Radiological Changes in the Treatment of Pancreatic Neuroendocrine Tumors (PNET) with Sunitinib: RECIST vs CHOI Criteria. CRIPNET-GETNE Study
Introduction: In PNET, phase III studies with antitarget drugs show few responses based on RECIST criteria despite a significant impact on progression free survival (PFS). Antiangiogenic drugs show in other tumors that responses are not always associated with a reduction in tumor volume on CT.
Conference: 14th Annual ENETS conference (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD Maria Pilar Solis-Hernandez
Keywords: sunitinib, PNET, choi, recist
#1076 “Wait and Watch” Approach for Small Pancreatic Neuroendocrine Tumors (pNETs): Prognosis and Survival in 51 Consecutive Patients.
Introduction: The most appropriate management for small non-functioning pancreatic neuroendocrine tumors (pNETs) is lacking and whether all these lesions should be routinely resected is still debatable
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Roberta Elisa Rossi
#1161 Comparative Proteomic Analysis of Human Insulinoma and Its Clinical Implications in Pancreatic Neuroendocrine Tumors
Introduction: Insulinoma is the most common functional PNET. Its molecular tumorigenesis is largely unknown and proteomic study on insulinoma has not been reported
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Yuan-Jia Chen
Authors: Qiao X W, Song Y L, Bai C M, Zhu L M, ...